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This study examined the 5-year survival of 2192 breast cancer women diagnosed between 1994 and 1997 in Ottawa, Canada, by
age, TNM stage, histology, grade and treatment, including assessment of the independent value of variables in defining prognosis. Our
results showed that age, stage, treatment and grade significantly influenced outcome regardless of the confounding factors considered,
with histology failing to achieve significant independent prognostic information. The survival rates were highest at ages 50–69 years
for stage I and at ages 40–49 years for stages II–IV. The rates were lowest at ages p39 years for stages I–II and at ages X70 years
for stages III–IV. The differences in survival between grade 1 and grade 3 were 9% in stage I and 20% in stage II. The treatment
leading to the best survival was surgery plus radiation for stages I–II and surgery combined with chemotherapy for stages III–IV.
Lobular carcinoma had a better prognosis than ductal carcinoma; this can be explained by more grade 1 and less grade 3 cases in
lobular carcinoma. The worse prognosis for young patients than other ages can be explained by their higher proportion of poorly
differentiated cancers. Stage I patients aged 50–69 years having the best survival is likely due to the earlier diagnosis achieved through
screening.
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Breast carcinoma is the most commonly diagnosed cancer (31% of
total) in women in Canada. As a cause of cancer mortality in
women, it is second only to lung carcinoma (25% lung vs 17%
breast) (National Cancer Institute of Canada, 2002). Cancer
survival is an essential component in cancer surveillance systems
that support cancer prevention and control. Survival with breast
cancer is associated with the value of prognostic factors such as
stage, age, histology and grade, and the effectiveness of treatment.
Numerous studies have documented the effect of age on 5-year
survival with breast cancer, and debate continues concerning
whether younger women have a poorer prognosis when diagnosed
with breast cancer. A Five-year prognosis has been found to be
poorer (Bonnier et al, 1995; Yildirim et al, 2000), better (La-Rosa
et al, 1996) or the same (Barchielli and Balzi, 2000) for women
diagnosed under age 35/40 years as compared with older women.
Stage has been shown to be a strong predictor of outcome for
female breast cancer, with survival declining as stage at diagnosis
increases (Taylor and Coates, 1997; Zahl and Tretli, 1997). The fact
remains, however, that wide variation in survival within stages
does exist, depending on such additional factors as age, histology
and grade. Histologic grade of a tumor can supply prognostic
information in addition to that provided by LRD (localized,
regional and distant) stage (Carriaga and Henson, 1995), but very
few studies have examined the pattern of cancer survival as a
function of grade within each TNM stage.
Multivariate analysis of data from a population-based cancer
registry, namely Ottawa Region Cancer Centre (ORCC), is used
here to examine the impacts of age and stage at diagnosis,
histology, histologic grade and treatment on 5-year survival of
female breast cancer in Ottawa, Canada.
MATERIALS AND METHODS
Analysis was conducted on 2192 cases of primary breast cancer
(International Statistical Classification of Diseases and Related
Health Problems, 10th revision [ICD-10], code 174) registered by
the ORCC between 1994 and 1997. The ORCC’s population-based
cancer registry covers all of Eastern Ontario and part of Western
Quebec. The reporting system is based on pathology and cytology
reports, clinical records and death certificates. This multiple
reporting practice provides an accurate and complete set of data
for each patient. Data regarding demographics, extent of disease,
tumour histology and survival were available for the study period.
All diagnoses were verified by histology. Patients were followed up
to 18 April 2000, and their survival status was obtained by active
follow-up, supplemented by passive follow-up involving record
linkage to the Ontario Mortality Database. At the time of data
analysis, we had survival information from 2181 patients (397
deaths, 1784 alive), and 11 (0.5%) were lost to follow-up. The
median follow-up time was 45 months. Exclusion criteria were as
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lfollows: patients living in the province of Quebec at the time of
diagnosis, diagnosis of cancer prior to lung cancer, report only by
autopsy or death certificate and in situ carcinoma.
Covariates included in the study were age and TNM stage at
diagnosis, histologic type, histologic grade and treatment. Tumour
stage was coded using the Combined American Joint Committee
on Cancer (AJCC) TNM classification system for disease stage at
the time of diagnosis (American Joint Committee on Cancer,
1997). The AJCC system takes into account information on tumour
size and tumour extension (T), regional lymph node involvement
(N) and the presence of distant metastasis (M). The grouped TNM
stage in this data included the pathologic stage group, augmented
by the clinical stage group when the pathologic stage was not
recorded. Age at cancer diagnosis was classified into four groups
(0–39, 40–49, 50–69, 70 years and over). Treatment was classified
as chemotherapy, radiotherapy, surgery, surgery with chemother-
apy, surgery with radiation, chemotherapy plus radiotherapy
(chemoradiation), surgery plus chemoradiation and no treatment
(including both patients who were untreated and those with
missing treatment informaion). The histology subtypes were
grouped according to ICD-10 codes. Three histology subsets were
defined: ductal carcinoma (8050, 8141, 8211, 8260, 8480, 8500,
8501, 8503, 8512 and 8530), lobular carcinoma (8520) and other
miscellaneous histology types. The histologic grade is the degree of
differentiation. Cases described as ‘well differentiated’ were
assigned grade 1; ‘moderately differentiated,’ grade 2; ‘poorly
differentiated,’ grade 3 and ‘ungraded (including grade Gx and
missing data),’ grade unknown.
Patient characteristics were compared using the w
2 heterogeneity
test for discrete data. All reported P-values were two-sided.
Relative survival is the preferred method for analysing the survival
of cancer patients in population studies. Relative survival rates
(RSRs) adjust for competing causes of death that would be
expected for persons of the same gender, age, period, and
geographic region as the breast cancer patients in the study,
without requiring information on the actual cause of death of each
patient. Relative survival analysis was performed in RELSURV and
Stata/Strel modules that both follow Este `ve’s maximum likelihood
method (Esteve et al, 1990). The expected survival rates were
derived by single year of age up to 106 from the gender-specific
Ontario life table for the study period. Statistical significance of
each covariate was assessed by the likelihood ratio test, using the
conventional level of 0.05. The goodness of fit for the models was
evaluated on the basis of the deviances. The prognostic importance
of TNM stage, histology, grade, age and treatment was analysed by
both uni- and multivariate relative survival models. The multiple
analysis was undertaken by taking into consideration all the
prognostic factors examined in univariate analysis. First-order
interaction terms were investigated for their effect on outcome by
considering change in deviance or the likelihood ratio test. Relative
excess risk (RER) was estimated from the relative survival model
(Preston, 1998).
RESULTS
The study showed that age, stage, grade and treatment had a
significant effect on 5-year survival in both uni- and multivariate
analyses, with histology failing to achieve significant independent
prognostic information (Table 1). Significant effect modifications
between stage and age/treatment were also observed (Po0.001).
In Table 1, RERs and their 95% confidence intervals (CIs) are
presented to assess the effect of each study variable on deaths due
to breast cancer. A significant increase in relative risk was observed
for stage IV diseases (relative risk of 52 compared to stage I in
univariate analysis and 26 in multivariate study). Relative excess
risk increases as grade goes from well-differentiated to poorly
differentiated tumours. Women younger than 40 years have a
relative risk over two times higher than women aged 50–69 years.
The risk of dying was significantly lower for patients who received
surgery or surgery plus radiotherapy than those who did not.
The overall 5-year RSR for 2192 women with breast cancer was
85%. The effect of each variable on survival in univariate analysis
is shown in Table 2. The 5-year survival declined significantly as
stage at diagnosis increased. The 5-year RSRs were 96% for stage I,
86% for stage II, 59% for stage III and only 26% for stage IV.
Patients younger than 40 years had the poorest 5-year prognosis,
whereas patients diagnosed at ages 50–69 years experienced better
survival than did women of other ages. Lobular carcinoma patients
had a higher survival probability than ductal carcinoma patients
through the follow-up. Significant survival declines were observed
for grades of moderately differentiated (88%) and poorly
differentiated (74%) compared to well differentiated (97%).
Within TNM stage, the presence of additional prognostic factors
had a great impact on 5-year relative survival (Table 3). Age had a
significant impact on survival within stage (P¼0.0009). For earlier
stage at diagnosis (I or II), women under 40 years had a much
poorer RSR as compared with the other age groups, and patients
diagnosed at ages 40–69 years experienced the best survival (50–
59 years in stage I, and 40–49 years in stage II). For later stage (III
or IV), patients aged 70 years and over had the poorest 5-year
prognosis, whereas patients diagnosed at ages 40–49 years
Table 1 Prognostic factor analysis of 2192 women with breast cancer, ORCC, 1994–1997
Univariate analysis Multivariate analysis
a Univariate analysis Multivariate analysis
a
Variables RER (95% CI) P-value
b RER (95% CI) P-value
b Variables RER (95% CI) P-value
b RER (95% CI) P-value
b
Stage 0.00000 0.00000 Age (years) 0.00005 0.00004
Stage I 1.00 1.00 0–39 1.00 1.00
Stage II 4.54 (2.32,8.89) 3.05 (1.55,5.99) 40–49 0.45 (0.29,0.68) 0.46 (0.30,0.71)
Stage III 15.64 (7.78,31.44) 8.28 (4.08,16.83) 50–69 0.29 (0.19,0.44) 0.45 (0.31,0.69)
Stage IV 52.35 (26.74,82.47) 25.80 (12.88,51.65) 70+ 0.47 (0.29,0.75) 0.85 (0.55,1.31)
Treatment 0.00000 0.00592 Histology 0.00257 0.08866
Chemotherapy 1.00 1.00 Ductal carcinoma 1.00 1.00
Radiotherapy 0.15 (0.06,0.40) 0.97 (0.42,2.23) Lobular carcinoma 0.50 (0.24,1.01) 0.66 (0.37,1.16)
Surgery 0.12 (0.06,0.25) 0.47 (0.24,0.94) Others 1.76 (1.16,2.66) 1.18 (0.80,1.74)
C+R
c 0.74 (0.44,1.27) 1.07 (0.63,1.81) Grade 0.00000 0.00007
S+C
c 0.25 (0.18,0.36) 0.58 (0.39,0.86) Grade 1 1.00 1.00
S+R
c 0.02 (0.01,0.12) 0.35 (0.15,0.81) Grade 2 7.26 (1.77,29.72) 2.68 (1.00,7.15)
S+C+R
c 0.19 (0.11,0.30) 0.53 (0.33,0.85) Grade 3 18.37 (4.55,74.16) 4.87 (1.84,12.87)
Relative survival rate (RER) estimated according to regression models based on relative survival.
aAdjusted for all the other variables in the table.
bP-value from likelihood ratio
test.
cC¼chemotherapy; R¼radiotherapy; S¼surgery.
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lexperienced better survival than did women of other ages. The
observed survival advantage in lobular carcinoma patients was also
seen within stage I, II and III. This would argue that the advantages
seen were not attributable to possible stage distribution differences
within histology groups. In addition, the discrepancies in survival
between ductal and lobular carcinomas were small for stage I or II
and much larger for stage III. Grading allowed the identification of
high- and low-risk subgroups within each stage group. For each
stage, survival rates decreased with advancing grade. The
differences in survival between grade 1 and grade 3 were 9% for
stage I and 20% for stage II. Therefore, poorly differentiated
tumours, even at an early stage, could have an impact on survival.
The interaction of grade with age was also investigated (Table 4).
Patients younger than 40 years had the poorest 5-year prognosis in
each grade group. The RSRs were highest at ages 40–49 years in
grade 1 group, and at ages 50–69 years in grade 2. For grade 3
disease, the RSRs were very close for women aged 40–49 years and
for those aged 50–69 years as well as for those in the 0–39 and
70þ years age groups, but women in the two middle-age groups
had substantially higher RSRs.
Treatment correlated significantly with patients’ survival
(Table 2), and the interaction of treatment and stage was more
predictive of outcome than any one factor separately (P¼0.0003,
Table 3). Patients with stage I or II breast cancer who were treated
by surgery plus radiation were more likely to survival than those
who received other treatments; patients with stage III or IV disease
who received surgery plus chemotherapy had better survival.
DISCUSSION
The TNM stage proved to be the most significant independent
prognostic factor for determining survival. In our study series,
around 75% of all patients were diagnosed in stages I and II.
Regular mammography combined with regular clinical breast
examination may offer the best opportunity to increase the
percentage of early stage cases detected. The frequency distribu-
tion of stage and the 5-year relative survival rates by stage were
similar to the data reported by the American Cancer Society
(American Cancer Society, 2001). The observed decline in overall
5-year survival by stage was also seen within each histology or
grade group. In all recent multiple regression analyses, stage had a
major prognostic role. This is probably due to the fact that stage
reflects the interaction between host and tumour. From this point
of view, some variables connected with the host such as age, or
connected with the tumour, such as histology and grade, could
stand out as prognostic factors.
Histology was found to be prognostic in breast cancer. Lobular
carcinoma had a better prognosis than ductal carcinoma for
separate or combined stages in our study, while Mclaughlin et al
(1995) had a similar result for combined stages. Although they
could not account for the stage distribution differences within
histology groups, these differences of survival can be explained
as follows: grade 1 lesion was more common in women who
had lobular carcinoma than in those who had ductal carcinoma
(51 vs 20% among the graded cases); and conversely, grade 3
lesion was identified less frequently in lobular carcinoma (12
vs 34%).
Histologic grade was an important determinant of prognosis
that also allowed risk stratification within a given tumour stage.
The proportion of high-grade cases increased with advancing
stage, whereas the percentage of low-grade cases decreased
(Table 3). This distribution would suggest that tumour with
advanced stage would be more likely to present at a higher grade.
The survival rates decreased with advancing grade within each
stage. This survival trend confirmed results reported by Carriaga
and Henson (1995). For most breast cancers, histologic grade was a
more meaningful prognostic feature than histologic classification,
and helped to explain the favourable prognosis of most special
histologic types. About 10% of low-grade tumours recurred within
5 years, compared with about 30% of high-grade cancers
(International Union Against Cancer, 2001).
We found that overall survival was poorer for those younger
than 40 years, and this difference was independent of tumour stage
and type of treatment. This finding was consistent with other
studies; for example Albain et al (1994) showed significantly worse
prognosis for younger patients even after other prognostic factors
were considered by multivariate analysis. The association of young
age at diagnosis with a worse prognosis in our series can be
explained by a higher proportion of poorly differentiated cancers
(50%) as compared with other age groups (aged 40–49, 40; 50–69,
29; and 70þ years, 24%), suggesting an aggressive breast cancer
phenotype. There are various possible explanations for the poor
survival experience of young women with breast cancer: (1) lack of
competing causes of death (Ederer et al, 1963); (2) higher
frequency of undifferentiated tumours, more poorly differentiated
cancer, microscopic lymph node involvement and negative
hormonal receptor status (Bonnier et al, 1995) or (3) more cases
diagnosed with stage II or III cancer (Gajdos et al, 2000). (In our
series, 55% of tumours for women aged 0–39 years were diagnosed
in stage II). Each of these hypotheses requires thorough
investigation.
Our finding that patients aged 50–69 years had the best
outcome can probably be explained by the relatively good local
control (through mammography screening) for this age group in
Canada, even though there is no significant difference in survival
among age groups 40–49, 50–59 and 60–69 years (whose 5-year
Table 2 Relative 5-year survival of breast cancer patients by age group,
TNM stage, histology, grade and treatment from univariate analysis, ORCC,
1994–1997
Relative survival (%) No. (%)
a
Rate 95% CIb Prognostic factor observations
Age at diagnosis (years)
0–39 147 (6.7) 69.9 60.5–77.5
40–49 448 (20.4) 84.2 79.3–88.1
50–69 972 (44.3) 88.4 84.9–91.4
70+ 625 (28.5) 81.3 74.9–86.2
TNM stage
c
Stage I 812 (37.0) 96.0 92.7–97.8
Stage II 843 (38.5) 85.6 81.7–88.7
Stage III 155 (7.1) 59.2 47.9–68.9
Stage IV 112 (5.1) 25.5 16.1–36.0
Histology type
Ductal carcinoma 1765 (80.5) 84.32 81.6–86.7
Lobular carcinoma 233 (10.6) 91.02 81.0–95.9
Others 194 (8.9) 76.65 67.7–83.4
Histologic grade
c
G1 (well differentiated) 346 (15.8) 97.2 90.9–99.1
G2 (moderately differentiated) 674 (30.8) 87.8 83.7–91.0
G3 (poorly differentiated) 474 (21.6) 73.9 68.0–78.9
Treatment
c
Chemotherapy 38 (1.7) 46.2 25.2–64.8
Radiotherapy 54 (2.5) 87.7 73.1–94.7
Surgery 188 (8.6) 89.1 77.2–94.9
Chemotherapy+radiotherapy 135 (6.2) 61.4 51.3–70.1
Chemotherapy+surgery 396 (18.1) 82.1 75.8–86.9
Radiotherapy+surgery 389 (17.8) 96.0 89.7–98.6
Chemotherapy+radiotherapy+surgery 972 (44.3) 77.4 73.3–80.9
aP-value of w
2 test for the changes in a variable structure was less than 0.0001 for each
variable considered.
bCI¼confidence interval.
cUnstaged (%)¼12.3, un-
graded¼31.8 and untreated or unknown¼0.9.
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lRSRs were 84, 88 and 88%, respectively). Some studies (Shapiro
et al, 1982; Miller et al, 1992) have indicated that mammography
screening has reduced breast cancer mortality and improved
survival by detecting cancers at earlier, more treatable stages. In
our study, nearly 96% of women with stage I cancers survived at
least 5 years; this stage accounted for 50% of the women aged 50–
69 years. In keeping with our results, Golledge et al (2000)
described that patients aged 60–69 years experienced the best
survival, although this favourable outcome was principally
restricted to axillary lymph node negative patients.
Determining the effect of patient age on breast cancer prognosis
is confounded by many factors, such as screening rates,
menopausal status and differences in treatment. Consequently,
significant differences in study designs have resulted in a lack of
consensus regarding the prognostic effect of patient age. La-Rosa
et al (1996) observed that women less than 35 years had a better
prognosis at 5 years from diagnosis. Holli and Isola (1997) found
that the 5-year RSR was highest in women aged 46–50 years,
whereas they found no significant difference between younger and
older age groups. A different finding for 5-year age-specific
survival by stage was reported from the Rhode Island Tumor
Registry, where women aged 40 years or less had a worse prognosis
than other age groups, except for those with stage I disease (Chung
et al, 1996). A limited number of young patients included in some
studies, differences in patient selection, age grouping and analysis
of outcome may contribute to the conflicting results for the
relationship between age and prognosis.
In our study series, proportionally more stage I patients (39%)
experienced surgery with radiotherapy, whereas more patients
with stages II, III and IV diseases underwent surgery with
radiotherapy and chemotherapy (57, 65 and 32%, respectively).
Selection of therapy depends not only on the stage of the disease,
but also on age, menopausal status, grade, histology, estrogen-
receptor (ER) and progesterone-receptor (PR) status, HER2/neu
gene amplification and general health. These factors may have
resulted in selection bias in this study. Preventive mastectomy is
an option to prevent breast cancer for women who are at very high
risk for breast cancer. Possible candidates for this procedure are
women with a strong family history of breast cancer and those who
have a mutation in genes p53, BRCA1, or have gene BRCA 2.
Chemotherapy can be considered for patients with hormone
receptor-negative disease or advanced cancer. Hormonal therapy
Table 3 Five-year relative survival for female breast cancer by TNM stage, age, histology, grade and treatment,
a ORCC, 1994–1997
TNM stage at diagnosis
I II III IV
No RSR (95% CI
b) No RSR (95% CI) No RSRSR (95% CI) No RSR (95% CI)
Age (years)
0–39 34 91.1 (74.6,97.1) 81 68.6 (55.1,78.8) 13 48.7 (18.5,73.6) 8 28.6 (6.0,57.4)
40–49 137 92.8 (83.8,96.9) 187 90.0 (82.3,94.5) 45 71.2 (52.5,83.6) 25 33.2 (12.4,55.9)
50–69 410 97.9 (92.3,99.5) 351 88.6 (82.3,92.7) 56 60.2 (40.6,75.1) 38 27.9 (12.8,45.4)
70+ 231 94.1 (79.7,98.4) 224 83.2 (71.9,90.2) 41 44.1 (22.3,64.0) 41 17.8 (6.6,33.2)
Histologic type
Ductal carcinoma 687 95.8 (92.0,97.8) 679 85.1 (80.9,88.4) 112 51.4 (38.7,62.7) 69 31.1 (17.8,45.3)
Lobular carcinoma 81 99.9 85 90.1 (71.8,96.8) 28 89.9 (45.9,98.5) 13 —
Histologic grade
G1 (well differentiated) 206 98.6 (91.2,99.8) 118 97.4 (75.5,99.8) 11 — 6 —
G2 (mostly differentiated) 296 94.6 (87.8,97.7) 295 87.4 (80.2,92.1) 48 69.7 (48.3,83.6) 17 —
G3 (poorly differentiated) 124 90.1 (75.6,96.2) 262 77.6 (69.6,83.7) 43 54.3 (35.1,70.1) 34 20.3 (4.5,43.9)
Treatment
Chemotherapy 2 — 12 62.2 (25.7,84.7) 4 — 12 —
Radiotherapy 36 93.7 (70.9,98.8) 8 73.1 (25.5,93.1) 2 — 2 —
Surgery 100 90.7 (75.1,96.7) 46 85.9 (55.2,96.2) 2 — 2 —
C+R
c 18 93.2 (46.8,99.3) 46 75.0 (57.6,86.1) 28 57.6 (32.8,76.2) 29 9.0 (1.5,25.0)
C+S
c 89 82.3 (68.6,90.5) 204 86.2 (77.3,91.8) 14 69.9 (24.6,91.2) 26 27.9 (9.6,49.8)
R+S
c 314 97.1 (89.8,99.2) 40 93.4 (49.9,99.3) 3 — 2 —
C+R+S
c 247 92.8 (85.9,96.4) 482 80.6 (75.0,85.0) 101 53.0 (39.3,64.9) 36 21.9 (8.7,38.9)
a—¼rate not reported. No. of cases less than 20 except for age; RSR¼relative survival rate.
bCI¼confidence interval.
cC¼chemotherapy; R¼radiotherapy; S¼surgery.
Table 4 Five-year relative survival for female breast cancer by age at diagnosis and histologic grade, ORCC, 1994–1997
Histologic grade
G1 (well differentiated) G2 (mostly differentiated) G3 (poorly differentiated)
No RSR (95% CI
a) No RSR (95% CI
a) No RSR (95% CI
a)
Age (years)
0–39 11 82.5 (46.0,95.3) 43 81.2 (65.7,90.2) 55 57.2 (39.4,71.5)
40–49 49 No deaths 144 85.8 (76.7,91.5) 130 80.9 (70.1,88.1)
50–69 181 96.5 (85.5,99.2) 294 90.1 (83.8,94.0) 196 79.9 (70.7,86.5)
70 and older 105 96.9 (44.4,99.8) 193 84.5 (72.4,91.6) 93 58.8 (41.9,72.3)
aCI¼confidence interval.
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lwith or without chemotherapy is usually assigned for receptor-
positive cancers.
Surgery plus radiotherapy plus chemotherapy would in general
be given to higher risk patients (with four or more positive axillary
nodes, large primary tumours, ER or PR negative, grade 2–3, 35
years of age and younger, etc.) than would surgery plus
radiotherapy alone; this was confirmed by our study in terms of
grade and age (the other variables were not included in this study)
within each stage (Table 5). In addition, radiotherapy might have
been given post mastectomy to patients with higher risk profiles
within a given stage, or with breast-conserving surgery to lower
risk patients. Treatment protocols were significantly linked to the
age at diagnosis for stage I, II and III (Pp0.01, Table 5): the
percentage of patients who received the three combined treatments
mainly decreased as age increased. Treatment differences between
younger and older patients may be partially attributed to the poor
physical condition and the comorbid diseases of the older patients.
Histology was not significantly related to selecting treatment for
stage I, II and III (Table 5).
Hormonal positive status predicts response to hormonal
therapy. Many studies have shown that women with ER- or PR-
positive cancers have a better prognosis than patients whose
cancers do not have these receptors. An interaction of treatment
with receptor status may partially explain the inferior results for
chemotherapy-treated patients. However, since hormonal receptor
status was missing for 93% of the patients in this series, the impact
of hormonal receptor status on outcome could not be accurately
assessed.
Table 5 Distribution of treatment by age at diagnosis, grade, histologic type and stage, ORCC, 1994–1997
Treatment
Frequency (percentage) Chemotherapy Radiation Surgery C+R
a C+S
a R+S
a C+R+S
a No treatment P-value
b
Stage I (age, years) 0.01
0–39 0 (0.0) 2 (5.9) 3 (8.8) 2 (5.9) 5 (14.7) 8 (23.5) 14 (41.2) 0 (0.0)
40–49 1 (0.7) 3 (2.2) 13 (9.5) 6 (4.4) 14 (10.2) 41 (29.9) 58 (42.3) 1 (0.7)
50–69 1 (0.2) 22 (5.4) 50 (12.2) 5 (1.2) 37 (9.0) 168 (41.0) 125 (30.5) 2 (0.5)
70 and older 0 (0.0) 9 (3.9) 34 (14.7) 5 (2.2) 33 (14.3) 97 (42.0) 50 (21.7) 3 (1.3)
Stage II o0.0001
0–39 1 (1.2) 0 (0.0) 2 (2.5) 7 (8.6) 10 (12.4) 1 (1.2) 60 (74.1) 0 (0.0)
40–49 1 (0.5) 1 (0.5) 7 (3.7) 9 (4.8) 42 (22.5) 7 (3.7) 119 (63.6) 1 (0.5)
50–69 2 (0.6) 5 (1.4) 12 (3.4) 17 (4.8) 87 (24.8) 11 (3.1) 217 (61.8) 0 (0.0)
70 and older 8 (3.6) 2 (0.9) 25 (11.2) 13 (5.8) 65 (29.0) 21 (9.4) 86 (38.4) 4 (1.8)
Stage III 0.002
0–39 0 (0.0) 1 (7.7) 0 (0.0) 3 (23.1) 0 (0.0) 0 (0.0) 9 (69.2) 0 (0.0)
40–49 0 (0.0) 0 (0.0) 0 (0.0) 5 (11.1) 2 (4.4) 0 (0.0) 38 (84.4) 0 (0.0)
50–69 1 (1.8) 1 (1.8) 1 (1.8) 14 (25.0) 2 (3.6) 0 (0.0) 36 (64.3) 1 (1.8)
70 and older 3 (7.3) 0 (0.0) 1 (2.4) 6 (14.6) 10 (24.4) 3 (7.3) 18 (43.9) 0 (0.0)
Stage IV 0.48
0–39 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 1 (12.5) 0 (0.0) 6 (75.0) 0 (0.0)
40–49 3 (12.0) 0 (0.0) 1 (4.0) 10 (40.0) 7 (28.0) 0 (0.0) 4 (16.0) 0 (0.0)
50–69 4 (10.5) 1 (2.6) 0 (0.0) 8 (21.1) 9 (23.7) 1 (2.6) 15 (39.5) 0 (0.0)
70 and older 5 (12.2) 1 (2.4) 1 (2.4) 10 (24.4) 9 (22.0) 1 (2.4) 11 (26.8) 3 (7.3)
Stage I (grades) o0.0001
G1 0 (0.0) 9 (4.4) 35 (17.0) 2 (1.0) 13 (6.3) 108 (52.4) 38 (18.5) 1 (0.5)
G2 1 (0.3) 17 (5.7) 29 (9.8) 5 (1.7) 34 (11.5) 110 (37.2) 98 (33.1) 2 (0.7)
G3 0 (0.0) 1 (0.8) 11 (8.9) 7 (5.7) 19 (15.3) 26 (21.0) 59 (47.6) 1 (0.8)
Stage II 0.04
G1 2 (1.7) 1 (0.9) 9 (7.6) 5 (4.2) 34 (28.8) 7 (5.9) 58 (49.2) 2 (1.7)
G2 1 (0.3) 1 (0.3) 16 (5.4) 18 (6.1) 65 (22.0) 14 (4.8) 179 (60.7) 1 (0.3)
G3 1 (0.4) 2 (0.8) 14 (5.3) 15 (5.7) 61 (23.3) 10 (3.8) 158 (60.3) 1 (0.4)
Stage III 0.19
G1 0 (0.0) 0 (0.0) 0 (0.0) 4 (36.4) 1 (9.1) 0 (0.0) 6 (54.6) 0 (0.0)
G2 1 (2.1) 0 (0.0) 1 (2.1) 5 (10.4) 8 (16.7) 1 (2.1) 32 (66.7) 0 (0.0)
G3 0 (0.0) 0 (0.0) 1 (2.3) 5 (11.6) 2 (4.7) 2 (4.7) 33 (76.7) 0 (0.0)
Stage IV 0.06
G1 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 2 (33.3) 0 (0.0)
G2 1 (5.9) 0 (0.0) 1 (5.9) 2 (11.8) 4 (23.5) 1 (5.9) 8 (47.1) 0 (0.0)
G3 1 (2.9) 0 (0.0) 1 (2.9) 6 (17.7) 11 (32.4) 0 (0.0) 15 (44.1) 0 (0.0)
Stage I (histologic type) 0.51
Ductal carcinoma 1 (0.2) 30 (4.4) 82 (11.9) 16 (2.3) 73 (10.6) 269 (39.2) 212 (30.9) 4 (0.6)
Lobular carcinoma 1 (1.2) 4 (4.9) 14 (17.3) 2 (2.5) 10 (12.4) 25 (30.9) 23 (28.4) 2 (2.5)
Stage II 0.52
Ductal carcinoma 10 (1.5) 7 (1.0) 31 (4.6) 37 (5.5) 165 (24.3) 30 (4.4) 394 (58.0) 5 (0.7)
Lobular carcinoma 1 (1.2) 0 (0.0) 7 (8.2) 2 (2.4) 23 (27.1) 6 (7.1) 46 (54.1) 0 (0.0)
Stage III 0.9
Ductal carcinoma 4 (3.6) 2 (1.8) 2 (1.8) 20 (17.9) 11 (9.8) 2 (1.8) 70 (62.5) 1 (0.9)
Lobular carcinoma 0 (0.0) 0 (0.0) 0 (0.0) 4 (14.3) 2 (7.1) 0 (0.0) 22 (78.6) 0 (0.0)
Stage IV 0.02
Ductal carcinoma 8 (11.6) 0 (0.0) 0 (0.0) 15 (21.7) 19 (27.5) 1 (1.5) 26 (37.7) 0 (0.0)
Lobular carcinoma 1 (7.7) 0 (0.0) 0 (0.0) 5 (38.5) 4 (30.8) 0 (0.0) 3 (23.1) 0 (0.0)
aC¼chemotherapy; R¼radiotherapy; S¼surgery.
bP-value of w
2 test.
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lThere are some other limitations to the study. Firstly, in the
assessments of multiplicative effects of patient characteristics (i.e.
interactions), the study did not have adequate power to produce
conclusive evidence for the study subgroups with small sample size
or inadequate end points (numbers of deaths). However, the
results were suggestive and can provide direction for future
research. For example, in the calculation of RSRs by age group for
patients with stage I cancer, the RSR estimates were not reliable
because of either the low frequency of death in this group or the
small number of patients in the youngest age subgroup, so they
need to be re-evaluated in a large series. To compensate for such a
deficit in expected sample size and end points, two major strategies
were used in this study: first, collapsing two adjacent groups into
one group and, second, reducing the number of intervals during
the analysis. Secondly, since information on cause of death was
missing for 86% of the individuals in this series, we used a relative
survival model, but the results could not be confirmed by Cox
proportional regression. However, the estimate of relative survival
is closer in theory to net survival, and empirical evidence shows
that relative survival approximates net survival more closely than
other methods (Esteve et al, 1990).
An important strength of this study is the ability to investigate
more comprehensively the impact of demographic, histologic and
therapeutic factors on survival with breast cancer. The size of the
study is sufficiently large to examine effect modifications and
perform survival analysis across different subgroups of breast
cancer. Perhaps more importantly, the results will provide further
evidence for the debates on age influences on survival and the
importance of grade on prognosis. In addition, one-quarter of
patients diagnosed with overt metastases were alive at 5 years. The
data thus provide fairly clear circumstantial evidence that the
society, which puts resources and energy into breast cancer
prevention and control through supporting integrated policy
development, surveillance, research, education, diagnosis and
treatment, has seen improved results. The development of new
chemotherapeutic agents, the use of new radiation techniques and
the implementation of multimodality therapy in advanced
disease (81% of stage IV patients received chemotherapy
combined with radiation and/or surgery in this study) have been
observed to improve survival in patients with more advanced
stages of disease.
In conclusion, our study has found that age and TNM stage at
diagnosis, histologic grade and treatment were independent
significant prognostic factors for breast cancer, whereas histologic
subtype was statistically significant in the univariate analysis but
not after adjusting simultaneously for other prognostic factors.
Even more information was obtained when prognostic factors were
examined in combination. Within stage, significantly wide
variation in survival was seen due to age or treatment. The fact
that lobular carcinoma had a better prognosis than ductal
carcinoma can be explained by more grade 1 and less grade 3
cases in lobular carcinoma. The worse prognosis for young
patients than other ages can be explained by their higher
proportion of poorly differentiated cancers. Stage I patients aged
50–69 years having the best survival may be due to the earlier
diagnosis achieved through screening. Although the analyses
involved small sample of some categories, our findings support
the existing literature concerning the prognostic effects of those
factors. The determination of prognosis depends on the accurate
assessment of prognostic factors and the appropriate choice of
therapeutic and supportive intervention. Further studies are
needed to confirm the results in a large sample and possibly to
ensure the inclusion of other factors such as menopausal status,
oestrogen receptor levels, progesterone receptor levels, number of
nodes and waiting time for treatment.
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